Myrexis is an American biopharmaceutical company based in Salt Lake City, Utah. It was focused on drug development in several areas of medicine, in particular cancer therapy and auto-immune diseases. It was developing three main cancer therapy drugs, Azixa, MPC-3100, and MPC-9528. After the failure of its most promising drug Azixa, in 2012, the company stopped all clinical trails and research and planned to be liquidated. However, instead of liquidation, the company stopped all activity and distributed most of its assets to shareholders, but continued as an entity looking for new investments. Wikipedia